SPECIMAN RESOURCE CORE

样本资源核心将利用现有的基础设施来满足翻译的广泛需求。 目前标本采集、诊断和分发不符合要求的两种皮肤癌研究 共享设施。该核心将从事收集、储存和分发各种标本， 试剂、样本分析和试剂验证。此外，它将制定新的方法， 多重样本分析、DNA和RNA提取和扩增、全面的数据库系统， 和计算分析。更具体地说，该核心将： 用于皮肤癌转化研究的标本，包括正常皮肤、黑色素细胞病变、黑色素瘤， BCC、血清和循环淋巴细胞，确保其适当储存、注释和及时分发给 SPORE研究者; B）协调痣/黑素瘤组织微阵列的构建和测试/细胞 阵列; c）验证抗体和TMA结果; d）建立和维护一个中央数据库程序， 必要的病理学、临床、流行病学、随访信息和基础研究数据， 与生物信息学/统计学核心相结合; e）提供特殊服务，如分析 用于临床试验、突变、染色质修饰和对新药的反应的标本; f）维持 并分发所需的经验证的试剂（抗体、寡核苷酸、DNA、RNA、质粒、蛋白质）， 肿瘤和细胞分析; g）率先开发新的标本诊断方法，例如 多重分析标记，分离和扩增程序的mRNA和DNA从稀缺的 标本; h）与耶鲁大学的共享设施和其他机构的类似资源建立联系， 包括其他孢子。该核心将与生物信息学，临床试验办公室， 免疫学，关键技术和遗传学共享耶鲁大学综合癌症中心的设施 中心标本资源中心的服务将提高翻译中心的有效运作， 以具有成本效益的方式在SPORE进行研究，并加快在实验台上应用发现， 临床实践和临床结果到基础研究。

The Specimen Resource Core will use existing infrastructure to address the broad needs of translational studies in two skin cancers that are not met by current specimen acquisition, diagnosis and distribution shared facilities. The core will engage in collecting, storing and distribution of a wide range of specimens and reagents, specimen analysis and reagent verification. In addition, it will develop new approaches for multiplex specimen analysis, DNA and RNA extraction and amplification, comprehensive database systems, and computational analysis. More specifically, the core will: a) build on and extend the current repertoire of specimens for translational studies in skin cancers, including normal skin, melanocytic lesions, melanoma, BCC, serum and circulating lymphocytes, ensuring their proper storage, annotation, and timely distribution to SPORE investigators; b) coordinate the construction of nevi/melanoma tissue microarrays and test/cell arrays; c) validate antibodies and TMA results; d) establish and maintain a central database program of essential pathological, clinical, epidemiological, follow-up information and basic research data that will be integrated with the bioinformatics/statistics core; e) provide special services such as the analysis of specimens for clinical trials, mutations, chromatin modification, and responses to novel drugs; f) maintain and distribute verified reagents (antibodies, oligonucleotides, DNA, RNA, plasmids, proteins) needed for tumor and cell analyses; g) spearhead the development of new approaches for specimen diagnosis, such as multiplex analysis of markers, isolation and amplification procedures for mRNA and DNA from scarce specimens; and h) establish links with shared facilities at Yale and similar resources in other institutions, including other SPOREs. This core will interact extensively with the Bioinformatics, Clinical Trial Office, Immunology, Critical Technologies, and Genetics shared facilities of the Yale Comprehensive Cancer Center. The services of the Specimen Resource Core will enhance the efficient operation of the translational studies in the SPORE in a cost-effective manner, and expedite the application of discoveries at the bench to clinical practice, and clinical results to basic research.